Teva's Turnaround

Can Teva Pharmaceutical CEO Kåre Schultz lead a successful turnaround for the underperforming company?

Kathryn Rudie Harrigan  | Spring 2018
Print this page


Teva Pharmaceuticals, the largest company domiciled in Israel, is a multinational pharmaceutical company that develops, manufactures, and distributes both patented and generic versions of ethical pharmaceuticals. In 2017, the company was in dire need of a turnaround plan based on a variety of factors: $17 billion in debt maturing in 2021; declining cash flows from its largest selling drug, Copaxone; intensified competitive challenges in its core generics business; and an inefficient organizational structure. In this case students are presented with detailed data on Teva’s financial circumstances as well as an overview of the challenges facing the global pharmaceutical industry in order to determine whether the company can avoid the need for Chapter 15 protection.

Case ID: 180410
Supplemental Materials: Teaching Note

Buy select cases through Ivey Publishing and Harvard Business Publishing.

Contact us by e-mail at Columbia CaseWorks or 646-745-8495.